ABTI Alpha-Beta Technology Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABTI Alpha-Beta Technology

ABTI 0.200

+99,900.0%

Jun 17 12:34 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Zachary Prensky who wrote (358)	7/31/1997 10:08:00 PM
From: Cacaito	of 572

GCSF is already a big selling product for Amgen, about $500 milllions in sales, second only to epogen $1 billion. It is a very succesful product for cancer and immunocompromised patients. It recently got bad press due to a study done for a non approved indication. No changes in sales so far. IMNX has a similar product GM-CSF (Leukine). Both are human derive products (hormone like) and very specific mode of action and big research and clinical studies of support. Betafectin is a very different product, non human, very general, non specific type of action, and it does stimulates macrophage(like GM-CSF, but not G-CSF). Betafectin is very safe compared with the other two (so far).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next